Woodstock Corp Increases Stake in Regeneron Pharmaceuticals

Biotech firm's shares acquired by investment firm in Q4 2025

Mar. 29, 2026 at 11:42am

Got story updates? Submit your updates here. ›

Woodstock Corp, an investment management firm, increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.3% in the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund now owns 18,646 shares of the biopharmaceutical company's stock, making it Regeneron's 22nd largest institutional investor.

Why it matters

Regeneron Pharmaceuticals is a prominent biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Institutional investor activity in the company's stock can signal broader market sentiment and provide insights into the firm's long-term growth prospects.

The details

Woodstock Corp's increased stake in Regeneron Pharmaceuticals comes as the biotech company continues to advance its pipeline of treatments for serious medical conditions. In the fourth quarter, Woodstock added 2,036 shares to its existing position, bringing the total value of its Regeneron holdings to $14.4 million.

  • Woodstock Corp increased its stake in Regeneron Pharmaceuticals in the fourth quarter of 2025.
  • The 13F filing disclosing the increased stake was submitted on March 29, 2026.

The players

Woodstock Corp

An investment management firm that has increased its stake in Regeneron Pharmaceuticals, making it the company's 22nd largest institutional investor.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Woodstock Corp's increased investment in Regeneron Pharmaceuticals reflects the biotech firm's continued prominence and growth potential in the pharmaceutical industry. As Regeneron advances its pipeline of innovative treatments, its stock remains an attractive target for institutional investors seeking exposure to the dynamic biotech sector.